La maladie de Parkinson (MP) est caractérisée par une perte progressive des terminaisons présynaptiques dopaminergiques et reste actuellement incurable. Néanmoins, dans les études épidémiologiques, il a été montré que l’utilisation des statines, médicaments hypocholestérolémiants, diminue le risque de développer une MP. Les statines sont également capables d'inhiber les effets neurodégénératifs dans les modèles précliniques in-vitro et in-vivo de la MP. Cependant, les mécanismes moléculaires à l’origine de ces effets neuroprotecteurs ne sont pas encore complétement élucidés. Ainsi, nous avons étudié les effets potentiels des statines sur l'expression des marqueurs synaptiques et sur le transport de la dopamine. Dans nos études, les statines induisent la croissance des neurites dans les cellules dopaminergiques et déclenchent une augmentation de l’expression des protéines synaptiques dopaminergiques telles que le transporteur vésiculaire des monoamines (VMAT2) et le transporteur de la dopamine. Les statines induisent une diminution de la recapture de la dopamine cellulaire et des changements d’affinités aux niveaux des sites de liaison des inhibiteurs sélectifs du VMAT2. L’activation du facteur de transcription nucléaire protéine-1 se liant à l'élément de régulation des stérols (SREBP-1), cholestérol-dépendent, serait l’élément inducteur de la surexpression des marqueurs dopaminergiques présynaptiques induite par les statines. En outre, ces résultats soutiennent un potentiel thérapeutique neuroprotecteur et/ou neurorestaurateur des statines précédemment proposées dans la MP et permettent de mettre en évidence de nouvelles cibles thérapeutiques comme le facteur SREBP. / Parkinson disease (PD) is characterized by a progressive loss of dopaminergic presynaptic terminals and remains incurable. However in epidemiological studies, it has been shown that the use of statins, which are hypocholesterolemic drugs, diminishes the risk to develop a PD. Statins are able to inhibit the neurodegenerative effects in in-vitro and in-vivo models of PD. However, the molecular mechanisms driving neuroprotective effects are not yet fully understood. Consequently, we investigated the potential effects of statins on the synaptic expression and dopamine transport function in the dopaminergic system. In our studies, statins enhance the neurite outgrowth in the dopaminergic cells and trigger an increase in the expression levels of presynaptic dopaminergic proteins such as vesicular monoamine transporter 2 (VMAT2) and dopamine transporter. Statins induce a reduction of dopamine cellular uptake and modulate the binding-affinity of the specific inhibitors for VMAT2. The activation of the nuclear transcriptional factor sterol regulatory element-binding protein 1 (SREBP-1), cholesterol-dependent, could be the key element of the overexpression of dopaminergic presynaptic markers induced by the statins. Furthermore, these findings highlight the therapeutic neuroprotective and/or neurorestorative potentials of statins previously proposed in PD and allow to bring out new potential therapeutic targets such as SREBP factor.

3,4-(±)-Methylenedioxymethamphetamine (MDMA, Ecstasy) is a widely abused amphetamine derivative with potent stimulant properties. The neuropharmacological effects of MDMA are biphasic in nature. MDMA initially causes synaptic monoamine release, primarily of serotonin (5-HT), producing hyperthermia and hyperactivity (5-HT syndrome). Conversely, the long-term effects of MDMA manifest as a prolonged depletion in 5-HT, and structural damage to serotonergic nerve terminals. Monoamine transporter systems at the plasma membrane and storage vesicles of 5-HT neurons have been implicated in MDMA toxicity. Nonetheless, many mechanistic questions remain regarding the precise role of uptake transporters in MDMA neurotoxicity. The present study was designed to address the importance of the serotonin reuptake transporter (SERT) and the vesicular monoamine transporter 2 (VMAT2) to the physiological, behavioral and neurotoxic responses to MDMA. SERT functions as a primary regulator of 5-HT homeostasis, mediating the reuptake of 5-HT from the synaptic space following its release during neurotransmission. SERT is a molecular target site for MDMA and many antidepressant agents such as the selective serotonin reuptake inhibitor (SSRI) class. Pharmacological inhibition of SERT protects against MDMA-induced serotonergic neurotoxicity. Thus, the effects of MDMA are in part mediated by an ability to interact with and inhibit SERT. Using a SERT-knockout (SERT-KO) rat model, we determined that SERT deficiency modulated the acute toxicities of MDMA, such as hyperthermia and hyperactivity, whilst completely preventing long-term depletions in tissue 5-HT levels, indicating the abolishment of neurotoxicity. Disruption of vesicular monoamine storage via interaction with VMAT2 has also been implicated in MDMA neurotoxicity. VMAT2 participates in the transport of monoamine neurotransmitters, in particular 5-HT and dopamine (DA), into intra-neuronal storage vesicles. As such, VMAT2 is critical in maintaining neuronal health by preventing neurotransmitter oxidation within the cytosol. Pharmacological inhibition of VMAT2 with Ro4-1284 reduced MDMA-induced hyperactivity and averted hyperthermia along with persistent serotonergic deficits. Overall, our results corroborate the hypothesis that SERT and VMAT2 are critical to the in vivo effects of MDMA. Furthermore, given that VMAT2 inhibition diminished the behavioral response to MDMA in rats, pharmacological manipulation of this transporter could be used in the treatment of MDMA abuse and overdose.

TRPM7 (Transient Receptor Potential Melastatin-like 7) is an ion channel necessary for the proper development of many cell types. Insight into the precise role of the channel in different cells has been hampered by the lethality of knocking out the gene in model organisms such as the mouse. Here I examine a zebrafish that has a loss-of-function mutation in the gene encoding Trpm7. First, I show that trpm7 is important for the function of developing dopaminergic neurons in the zebrafish. Second, I examine the interaction between trpm7 and the related gene vmat2 in order to develop a cellular mechanism of trpm7 function in presynaptic dopaminergic neurons. Finally, I investigate the necessity of the kinase and ion channel domains of trpm7 in their ability to promote pigmentation in melanophores as a model cell type. Based on the results from these experiments and observations from other researchers, I form a new hypothesis for Trpm7 function in protein sorting. These studies provide a detailed and novel analysis of the function of an ion channel that is necessary for life.

In der vorliegenden Arbeit wurde die Regulation der Aktivität der vesikulären Monoamintransporter VMAT1 und VMAT2 durch heterotrimere G-Proteine untersucht. In der humanen neuroendokrinen Zellinie BON werden VMAT1 und VMAT2 exprimiert. Sie colokalisieren in diesen Zellen mit der a-Untereinheit des heterotrimeren G-Proteins Go2 vorwiegend auf großen elektronendichten Vesikeln, den LDCVs. Die Aktivität beider Transporter unterliegt einer Regulation durch Gao2. Nach Aktivierung des G-Proteins kommt es zu einer Hemmung der vesikulären Monoaminaufnahme. Die Aktivität von VMAT2 wird dabei empfindlicher reguliert als die Aktivität von VMAT1. In Primärkulturen von Rapheneuronen der Ratte wird VMAT2 als neuronale Variante des Transporters exprimiert. VMAT2 lokalisiert in diesen Neuronen überwiegend auf kleinen synaptischen Vesikeln, den SSVs. Hier kommt es zu einer Colokalisation mit Gao2 auf diesem Vesikeltyp. Auch in Rapheneuronen wird die Aktivität von VMAT2 durch diese G-Protein Untereinheit gehemmt. Elektronenmikroskopische Befunde belegen die Lokalisation von VMAT2 und Gao2 auf SSVs von serotonergen Axonterminalen im präfrontalen Cortex der Ratte. An einer Präparation synaptischer Vesikel aus diesem Gehirnbereich konnte ebenfalls eine Hemmung der Transportaktivität von VMAT2 durch Gao2 nachgewiesen werden. Auch in Thrombozyten der Maus unterliegt die vesikuläre Serotoninaufnahme einer Hemmung durch ein heterotrimeres G-Protein. In chronisch entleerten Vesikeln aus Mäusen, in denen das Gen für die periphere Tryptophanhydroxylase deletionsmutiert vorlag, konnte zunächst keine Hemmung der Serotoninaufnahme durch heterotrimere G-Proteine beobachtet werden. Nach Vorbeladung der Vesikel mit Serotonin war dies jedoch der Fall. Die Aktivierung des G-Proteins wird somit sehr wahrscheinlich über den Füllungszustand der Vesikel gesteuert. / In this study we investigated the regulation of the activity of the vesicular monoamine transporters VMAT1 and VMAT2 by heterotrimeric G-proteins. In the human neuroendocrine cell line BON both transporters are expressed. They colocalize in these cells with the a-subunit of the heterotrimeric G-protein Go2 predominantely on Large Dense Core Vesicles (LDCVs). The activity of both VMAT1 and VMAT2 is regulated by Gao2. G-protein activation results in a down-regulation of vesicular monoamine uptake. VMAT2 appears to be more sensitive towards the observed G-protein regulation than VMAT1. Serotonergic raphe neurons in primary culture express VMAT2 as the neuronal form of the transporter. In these neurons VMAT2 predominantely localizes to Small Synaptic Vesicles (SSVs). Here, VMAT2 colocalizes with Gao2 on SSVs. In these neurons Gao2-dependent down-regulation of VMAT2 activity was observed, too. Immunoelectron microscopic analysis confirmed a localization of VMAT2 and Gao2 on SSVs from serotonergic terminals in the rat prefrontal cortex. In addition, Gao2-dependent regulation of VMAT2 activity could also be demonstrated when using a crude synaptic vesicle preparation of this brain area. Even in platelets obtained from mice the vesicular serotonin uptake is down-regulated by heterotrimeric G-proteins. In serotonin-depleted platelets from peripheral tryptophane-hydroxylase knockout mice no G-protein-dependent down-regulation of monoamine uptake was observed. After preincubation of the platelets with serotonin, the G-protein regulation was restored. Therefore, the vesicular transmitter content appears to be a likely factor of G-protein activation in platelets.

Physical activity can prevent cardiovascular disease, obesity, type II diabetes and some types of cancer. With only 3.5% of adults meeting the recommended physical activity guidelines, research has focused on the regulatory factors that influence physical activity level. Genetic influence accounts for the majority of physical activity regulation. However, there is limited information on the mechanisms that affect physical activity, in part, because of a lack of reliable methods to silence genes in vivo. The purpose of this dissertation was to identify mechanisms in skeletal muscle that influence physical activity. The methods used to accomplish the purpose of this dissertation were the evaluation of Vivo-morpholinos as a gene silencing tool in skeletal muscle and brain, identification of proteins in skeletal muscle associated with increased physical activity level, and the use Vivo-morpholinos to transiently knockdown the identified skeletal muscle proteins as a means to elucidate mechanisms for the peripheral regulation of physical activity. Overall, this study showed that Vivo-morpholinos effectively silenced genes in skeletal muscle yet required the use of a pharmacological aid to achieve gene silencing in the brain. Additionally proteins associated with calcium regulation (Annexin A6 and Calsequestrin 1) and the Kreb’s (TCA) cycle were found to be over expressed in the high active animals. The knockdown of Annexin A6 and Calsequestrin 1 resulted in a significant decrease in physical activity, thus showing that calcium regulation could influence the physical activity response. While these results provide a potential mechanism for the peripheral regulation of physical activity, a side effect observed was that Vivo-morpholinos can hybridize resulting in increased mortality rates of the treatment animals. Therefore, we developed methods to alleviate the toxic effects of Vivo-morpholinos. Thus, this dissertation refined a technique for determining a gene’s effect in an in vivo model and identified two candidate proteins (Annexin A6 and Calsequestrin 1) that play a role in regulating daily physical activity.

No description available.

No description available.

No description available.